Rowley et al. 55F Glioblastoma with Recurrent Disease

by Benny | Apr 27, 2021

MultiHance® 9 Image Library 9 Rowley et al. 55F Glioblastoma with Recurrent Disease MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Omniscan™ (gadodiamide)1 The ENHANCE Study Rowley et al. 55-year-old...

Maravilla et al. 51F Metastatic Lung Cancer

by Benny | Apr 27, 2021

MultiHance® 9 Image Library 9 Maravilla et al. 51F Metastatic Lung Cancer MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Magnevist® (gadopentetate dimeglumine)1 Maravilla et al.51-year-old woman with...

Colosimo et al. 72F Primary Cerebral Lymphoma

by Benny | Apr 21, 2021

MultiHance® 9 Image Library 9 Colosimo et al. 72F Primary Cerebral Lymphoma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.72-year-old woman with primary...

Colosimo et al. 50M Metastatic Renal Carcinoma

by Benny | Apr 21, 2021

MultiHance® 9 Image Library 9 Colosimo et al. 50M Metastatic Renal Carcinoma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.50-year-old man with metastatic...

Colosimo et al. 52F Primary Glioma

by Benny | Apr 21, 2021

MultiHance® 9 Image Library 9 Colosimo et al. 52F Primary Glioma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.52-year-old woman with primary glioma These...